Efficacy of Dihydroartemisinin for Treating PCOS - Trial NCT06417099
Access comprehensive clinical trial information for NCT06417099 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanghai Zhongshan Hospital and is currently Recruiting. The study focuses on Polycystic Ovary Syndrome. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Zhongshan Hospital
Timeline & Enrollment
Phase 2
May 01, 2024
May 01, 2025
Primary Outcome
Recovery of regular menses
Summary
The primary research hypothesis of this study is that dihydroartemisinin is effective in
 restoration of regular menstrual cycles of PCOS subjects who meet at least two of three
 Rotterdam Criteria. Secondary research hypotheses include: dihydroartemisinin is also
 effective in reducing androgen, total immature follicles, and anti-Mullerian hormone.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06417099
Non-Device Trial